Updated November 2026
The SSCP is a publicly available summary of the main safety and clinical performance information for certain medical devices, required under Regulation (EU) 2017/745 (MDR).
This guide explains what SSCP means, which devices require one, what information it contains, and how it relates to technical documentation, post-market surveillance and the European database on medical devices, EUDAMED.

In this guide
- What is an SSCP?
- Which devices require an SSCP?
- What information does it contain?
- Who is it intended for?
- Who prepares and validates it?
- Updates and post-market surveillance
- SSCP and EUDAMED
What is an SSCP?
SSCP stands for Summary of Safety and Clinical Performance. Its main legal basis is Article 32 of Regulation (EU) 2017/745.
The document provides public access to information about the medical device and the clinical evidence supporting its safety and performance.
The information in the SSCP is drawn from the device’s technical documentation, including documents relating to clinical evaluation, risk management and post-market surveillance.
SSCP does not replace the instructions for use, the technical documentation or the mandatory information provided on the implant card.
Which devices require an SSCP?
Article 32 of the MDR requires an SSCP for implantable devices and class III devices, other than custom-made or investigational devices.
The requirement is therefore not limited to class III: it also covers implantable devices in other classes.
A distinction applies to legacy devices, which continue to be placed on the market under the transitional provisions of Article 120 of the MDR, subject to the conditions set out in the Regulation.
MDCG 2021-25 rev.1 clarifies that the SSCP requirement under Article 32 does not apply to these legacy devices.
Distinguishing between MDR devices and devices benefiting from the transitional provisions is therefore important when determining whether an SSCP is required.
What information does it contain?
Article 32(2) sets out the information to be included in the SSCP.
This includes:
- identification of the device and the manufacturer, including the Basic UDI-DI, the basic device identifier, and the single registration number (SRN), if already issued;
- the intended purpose, indications, contraindications and target populations;
- a description of the device, including any previous generations or variants and the differences between them, together with any relevant accessories, other devices and products intended to be used in combination with it;
- information on any residual risks and any undesirable effects, warnings and precautions;
- a summary of the clinical evaluation and relevant information on post-market clinical follow-up (PMCF);
- possible diagnostic or therapeutic alternatives;
- the suggested profile and training for users;
- references to any harmonised standards and common specifications applied.
MDCG 2019-9 rev.1 provides a recommended structure for organising and presenting this information, together with guidance on readability and revision history.
The recommendations in the MDCG guidance should be distinguished from the requirements laid down in the Regulation itself.
Who is it intended for?
The SSCP is intended for the device’s intended users and, where relevant, patients.
MDCG 2019-9 rev.1 distinguishes between a part intended for professional users and, where relevant, a separate part intended for patients.
The information must be clear to each audience. Medical terminology, clinical findings and risk information therefore need to be presented at an appropriate level, while remaining consistent with the available evidence.
The MDCG guidance also addresses language and readability considerations in relation to the intended audience and the markets concerned.
Who prepares and validates it?
Manufacturer draws up the SSCP using the device’s technical documentation and submits the draft to the notified body involved in the conformity assessment.
The notified body validates the summary after checking that the required information is included, accurately presented and consistent with the relevant technical documentation.
The timing of validation depends on the device class and the applicable conformity assessment procedure.
MDCG 2019-9 rev.1 describes, in particular, specific arrangements for implantable devices whose technical documentation is assessed on a sampling basis.
Updates and post-market surveillance
The SSCP must remain consistent with the current technical documentation and the available information on the device’s safety and clinical performance.
Relevant processes and documents include:
- post-market surveillance (PMS), through which information on the device is collected and analysed after it has been placed on the market;
- post-market clinical follow-up (PMCF), involving the ongoing collection and evaluation of clinical data;
- the periodic safety update report (PSUR), required under Article 86 of the MDR for the relevant device classes.
MDCG 2019-9 rev.1 links the review of the SSCP to updates to clinical and safety documentation, particularly the PMCF evaluation report and the PSUR.
A review does not necessarily require changes to the text. The content needs to be updated when new information means that the existing summary is no longer accurate or complete.
The MDCG guidance also addresses the validation of updates in relation to the nature of the changes and the notified body’s activities.
SSCP and EUDAMED
The MDR requires the SSCP to be made available to the public through EUDAMED, the European database on medical devices.
Article 32 also requires the manufacturer to indicate on the label or in the instructions for use where the summary is available.
Use of the first four EUDAMED modules has been mandatory since 28 May 2026:
- Actor registration;
- UDI/Devices registration;
- Notified Bodies & Certificates;
- Market Surveillance.
Mandatory use forms part of the gradual roll-out introduced by Regulation (EU) 2024/1860, which includes transitional provisions for specific obligations.
For SSCP management, MDCG 2026-4 rev.1, originally published in June 2026 and updated by revision 1 in October 2026, describes the planned transfer of the task of uploading documents to EUDAMED from notified bodies to manufacturers.
The document retains the notified body’s role in validating the SSCP and distinguishes this from uploading the validated summary and its translations.
The change depends on the availability of the new functionality in the EUDAMED Production environment. MDCG 2026-4 rev.1 indicates a planned deployment in December 2026.
MDCG 2026-4 rev.1 also describes an interim arrangement under which the notified body continues to upload the master version of the SSCP until the new functionality is fully available.
For devices placed on the market before mandatory use of the UDI/Devices module and for which an SSCP is required, MDCG 2026-4 rev.1 indicates that manufacturers should upload the summaries as soon as possible, and no later than 27 March 2027, coordinating their activities with the notified bodies.
MDCG 2026-4 rev.1 is a non-legally binding position paper and should be read alongside the applicable legal provisions. Operational arrangements for managing documents need to take account of the functionality actually available and the current EUDAMED documentation.
Why this guide is not an SSCP template
This page explains the purpose and general regulatory framework of the SSCP. It does not provide a completed template or a summary for a particular medical device.
The information included in an SSCP depends on the device’s characteristics, intended purpose, intended audience and relevant clinical evidence.
This guide is therefore for information only and does not establish procedures for preparing, validating or updating an SSCP for an individual product.
Informational note
This guide is published for informational purposes only and does not constitute regulatory, legal, technical or professional advice.
The information is based on publicly available sources and was verified as of the date of publication or the latest update of this page. It may therefore not reflect subsequent changes or developments.
For assessments relating to specific cases, reference should be made to the official texts, the latest documentation issued by the competent authorities and, where appropriate, qualified professionals.
Official sources
- Regulation (EU) 2017/745 — EUR-Lex: in particular Articles 32, 61, 83, 86 and 120.
- MDCG 2019-9 rev.1 — Summary of safety and clinical performance
- MDCG 2021-25 rev.1 — Application of MDR requirements to legacy devices
- MDCG 2026-4 rev.1 — Management of SS(C)P in EUDAMED after mandatory use
- European Commission — EUDAMED overview
Share this guide
If you find this guide useful, you can share it with other professionals interested in MDR.
Want to stay updated on MDR and IVDR?
Subscribe to MDN – Medical Device News for free.
Subscribers receive the newsletter by email every Monday, one week before publication on the website.
Related resources
- What is the MDR?
- MDR Notified Bodies
- MDR Classification Rules
- MDR Codes
- MDR Harmonised Standards
- MDR Post-Market Surveillance
- UDI and Basic UDI-DI
- Medical Device Clinical Evaluation
Copyright and reuse
© Simone Ronco. Unless otherwise stated, the editorial content of this guide is an original work.
Short excerpts may be quoted with attribution to the author and a link to the original page.
Full reproduction, translation, adaptation or commercial use of the content requires prior written permission.